Impact of the main implantable cardioverter-defibrillator trials for primary and secondary prevention in Italy: a survey of the national activity during the years 2001-2004.
Several trials demonstrated the lifesaving role of implantable cardioverter-defibrillator (ICD) in high-risk groups of patients. Aim of this review was to report the clinical characteristics of patients enrolled in the ICD Registry of the Italian Association of Arrhythmology (AIAC) in the years 2001-2004. The Registry collects prospectively 85% of national ICD implantation activity on the basis of European ICD form (EURID). The number of implanted ICDs in Italy was 2,418 in the year 2001, 3,992 in the year 2002, 5,595 in the year 2003, and 7,190 in the year 2004. The number of ICDs per million of inhabitants was 42.1 in the year 2001 (+11.8% respect to 2000), 70.0 in the year 2002 (+65.1% respect to 2001), 98.3 in the year 2003 (+40.4% respect to 2002), and 125.0 in the year 2004 (+27.2% respect to 2003). The median age was 67 years in the years 2001-2002, 68 years in the years 2003-2004. The main indications during the study were syncope (24.2-14.9%) and cardiac arrest (28.5-17.3%), followed by palpitations and dizzy spells (15.5-17.2%, and 9.4-6.9% of patients, respectively). The use of prophylactic ICD had a fourfold increase in the examined period (5.8% in 2001, 22.9% in 2004). Ventricular tachycardia was the main arrhythmic indication in 44.4-54.6% of cases, ventricular fibrillation in 11.8-18.0%, both in 3.5-6.5%. In the years 2002, 2003, and 2004 single chamber ICDs were implanted in 45.5%, 38.8%, and 33.7% of patients, dual chamber ICDs in 35.1%, 32.3%, and 30.5%, biventricular ICDs in 19.4%, 28.9%, and 34.7%, respectively. The ICD implantation rate in Italy increased significantly in the period 2001-2004, similarly to the trend in other western countries. The Registry showed an important increase of prophylactic and dual or triple chamber ICDs use.